NDA 50562, held by Bayer Pharms. Azlocillin Sodium.
As of Nov 13, 2026, NDA 50562 (Azlin), held by Bayer Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| AzlinEQ 2GM BASE/VIAL · injectable;injection | Azlocillin Sodium | Discontinued |
| AzlinEQ 3GM BASE/VIAL · injectable;injection | Azlocillin Sodium | Discontinued |
| AzlinEQ 4GM BASE/VIAL · injectable;injection | Azlocillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters